Article Text

PDF
SAT0564 Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
  1. A. Kavanaugh1,
  2. D. Gladman2,
  3. D. van der Heijde3,
  4. O. Purcaru4,
  5. P.J. Mease5
  1. 1Division of Rheumatology, Allergy and Immunology, UCSD, San Diego, United States
  2. 2University of Toronto, Toronto, Canada
  3. 3Leiden University Medical Center, Leiden, Netherlands
  4. 4UCB Pharma, Brussels, Belgium
  5. 5Swedish Medical Center and University of Washington, Seattle, United States

Abstract

Background Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 Few studies have evaluated the association between improvements in workplace and household productivity and symptom relief with available therapies in PsA pts.

Objectives To evaluate the association between improvements in clinical and pt-reported outcomes (PROs) and improvements in productivity in the workplace and at home in PsA pts treated with certolizumab pegol (CZP).

Methods Associations between clinical outcomes or PROs and work and household productivity outcomes were compared using data from the double-blind and placebo-controlled period of RAPID-PsA (to Wk24; NCT01087788).2 Clinical outcomes included achievement of ACR20/50, PsARC and PASI75 responses and DAS28 remission (DAS28<2.6). PROs included achievement of MCID for HAQ-DI (≥0.3 decrease from baseline [BL]), pain (≥10 mm decrease from BL) and fatigue (≥1 decrease from BL). Responders and non-responders at Wk24 for clinical outcomes and PROs were compared in terms of change from BL (CFB) in workplace and household productivity, as assessed using the validated arthritis-specific Work Productivity Survey (WPS).3 Analyses were carried out for pts originally randomized to CZP. Groups were compared using a non-parametric bootstrap-t method. Missing data were imputed using last observation carried forward for WPS outcomes and non-responder imputation for clinical outcomes and PROs.

Results 273 CZP pts entering RAPID-PsA were included in Wk24 analyses. 61.9% of pts were employed at Wk24. Overall, pts achieving a clinical or PRO response at Wk24 also reported greater improvements in workplace and household productivity than non-responders (Table). Improvements in both joint and skin symptoms and clinically meaningful reductions in disability, pain and fatigue were associated with improved workplace absenteeism and presenteeism. Responders also reported greater improvements in their participation in family, social and leisure activities (data not shown). Results should be interpreted with caution due to differences in the number of pts between responder and non-responder groups, and because the analyses were not adjusted for differences in BL productivity between these groups.

Conclusions Clinical responses in joint and skin outcomes as well as clinically meaningful improvements in PROs are associated with improved workplace and household productivity in PsA pts treated with CZP.

References

  1. Mau W. J Rheumatol 2005;32:721–728.

  2. Mease P. J. Ann Rheum Dis 2014;73:48–55.

  3. Osterhaus J. Arthritis Res Ther 2014;16:R140.

Disclosure of Interest A. Kavanaugh Grant/research support from: Abbott, Amgen, BMS, Pfizer, Roche, Janssen, UCB Pharma, D. Gladman Grant/research support from: Abbott, Bristol Myers Squibb, Celgene, Johnson & Johnson, MSD, Novartis, Pfizer, UCB Pharma, Consultant for: Abbott, Bristol Myers Squibb, Celgene, Johnson & Johnson, MSD, Novartis, Pfizer, UCB Pharma, D. van der Heijde Grant/research support from: AbbVie, Amgen, AstraZeneca, Augurex, BMS, Boehringer Ingelheim, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli-Lilly, Galapagos, GSK, Janssen, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, UCB Pharma, Vertex, Consultant for: AbbVie, Amgen, AstraZeneca, Augurex, BMS, Boehringer Ingelheim, Celgene, Centocor, Chugai, Covagen, Daiichi, Eli-Lilly, Galapagos, GSK, Janssen, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, UCB Pharma, Vertex, Employee of: Director of Imaging Rheumatology bv, O. Purcaru Employee of: UCB Pharma, P. Mease Grant/research support from: (Abbott) AbbVie, Amgen, BiogenIdec, BMS, Celgene, Crescendo, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB Pharma, Consultant for: (Abbott) AbbVie, Amgen, BiogenIdec, BMS, Celgene, Covagen, Crescendo, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB Pharma, Speakers bureau: (Abbott) AbbVie, Amgen, BiogenIdec, BMS, Celgene, Crescendo, Genentech, Janssen, Lilly, Pfizer, UCB Pharma

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.